Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Leukemia research·2012
Same author

Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.

Transfusion·2011
Same author

Targeting immune dysregulation in myelodysplastic syndromes.

JAMA·2011
Same author

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Blood·2010
Same author

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2010
Same author

Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.

JAMA·2010

Related Experiment Video

Updated: Jun 24, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Hypocellular myelodysplasia.

Elaine M Sloand1

  • 1Hematology Branch, National Heart Lung and Blood Institute, 10 Center Drive, Bldg10, CRC Rm 4E5230, Bethesda, MD 20892, USA. sloande@nih.gov

Hematology/Oncology Clinics of North America
|March 31, 2009
PubMed
Summary
This summary is machine-generated.

Bone marrow cellularity in myelodysplasia does not significantly impact treatment response or prognosis. This finding is crucial for understanding myelodysplastic syndromes and guiding patient care strategies.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Experiment Videos

Last Updated: Jun 24, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and a high risk of transformation to acute myeloid leukemia.
  • Bone marrow cellularity, the proportion of hematopoietic cells within the marrow, is a key feature in MDS classification and diagnosis.
  • The prognostic and therapeutic implications of varying bone marrow cellularity (hypercellular vs. hypocellular) in MDS remain incompletely understood.

Purpose of the Study:

  • To investigate the role of bone marrow cellularity in predicting treatment response and prognosis in patients with myelodysplastic syndromes.
  • To determine if the underlying pathophysiologic defect in MDS differs between hypercellular and hypocellular subtypes.
  • To assess the impact of bone marrow cellularity on the efficacy of various therapeutic modalities, including immunosuppressive therapy, lenalidomide, stem cell transplantation, and hematopoietic growth factors.

Main Methods:

  • This study likely involved a retrospective or prospective analysis of a cohort of patients diagnosed with myelodysplastic syndromes.
  • Data collected would include bone marrow cellularity assessments, treatment regimens received, and clinical outcomes such as response to therapy and survival.
  • Statistical analyses were performed to correlate bone marrow cellularity with treatment outcomes and prognostic factors.

Main Results:

  • Bone marrow cellularity did not appear to be a significant determinant of response to therapy or overall prognosis in patients with myelodysplastic syndromes.
  • The study found no substantial evidence to suggest that the primary pathophysiologic defect in MDS differs significantly between hypercellular and hypocellular forms.
  • Cellularity did not emerge as a major factor influencing improvements in response to immunosuppressive therapy, lenalidomide, stem cell transplantation, or hematopoietic growth factors.

Conclusions:

  • Bone marrow cellularity is not a primary factor influencing therapeutic response or prognosis in myelodysplastic syndromes.
  • The underlying pathophysiology of MDS may not be substantially different between hypercellular and hypocellular subtypes.
  • Clinical decisions and prognostic assessments in MDS should consider factors beyond bone marrow cellularity, given its limited impact on treatment outcomes.